A theoretical analysis of the orientation of biofunctionalized thiolate has been made by changing the surface configuration. The results show that it is possible to match the experimental data by changing the molecular density and also that it is possible to match the experimental data using only hollow sites in the gold surface as placements for the molecules. Some configurations that match available data using only hollow sites positions have been suggested. Moving away from the (sqrt(3) x sqrt(3)) R30° configuration result in a large energy gain for Bor Capped.

No description available.

Acute Lymphoblastic Leukemia (ALL) is one of the most common type of hematologic malignancy in children, characterized by an excessive proliferation of unfunctional immature lymphoblasts in the blood and the bone marrow, which leads to a range of severe blood-related complications. Given the remarkable increase in the prevalence of leukemia in the past 20 years, there has been a particular interest in the development of in vitro experimental models for cancer research. Ultra-short self-assembling peptides have shown to be a promising class of synthetic biomaterials due to their biocompatibility, tunable mechanical properties, and the possibility of controlling the scaffold composition. The objective of this study was to create a bioactive but well-defined synthetic 3D model of the bone marrow (BM) microenvironment for the simulation of ALL using biofunctionalized ultrashort self-assembling peptide scaffolds. Different bioactive motifs derived from integral extracellular matrix (ECM) constituents that are known to enhance cell-matrix adhesion, including RGDS from fibronectin, YIGSR from laminin, and GFOGER from collagen, were incorporated into the parent peptide IIZK. These peptides demonstrated to be capable of generating stable hydrogel structures composed of fibrous porous networks, each with unique nanofiber morphology and mechanical properties. All the peptide scaffolds that were investigated in this study exhibited optimal characteristics concerning the cytocompatibility of multiple BM niche cells, including human bone marrow mesenchymal stem cells (MSCs), human umbilical vein endothelial cells (HUVECs), and patient derived ALL cells. The suitability of the scaffolds as drug screening platforms was evaluated, demonstrating their potential as versatile tools for the assessment of drug efficacy.

Dans des modèles expérimentaux, une tolérance d'allogreffe a pu être induite en transférant des lymphocytes T CD4+ régulateurs (Treg) spécifiques d'antigènes (Ag) du donneur expandus ex vivo. Les données ont démontré l'importance des Treg d'allospécificité indirecte (Treg indirects) dans l'induction d'une tolérance à long terme. L'expansion de Treg indirects ex vivo est problématique, principalement à cause de la difficulté d'obtenir en grand nombre des cellules présentatrices d'antigène autologues (CPA)pour stimuler les Treg. Les lymphocytes B (LB) sont des APC accessibles, présentes en grand nombre et ont un fort potentiel régulateur. Cependant, l'utilisation de LB autologues comme APC est rendue problématique par leur incapacité à présenter les Ag dont ils ne sont pas spécifiques.Dans ce travail de thèse, nous avons développé une approche nanobiotechnologique permettant de transformer des LB polyclonaux autologues en puissants stimulateurs de Treg spécifiques de l'Ag.Des Ag particulaires synthétiques (SPAg) ont été générés en fixant sur des nanosphères fluorescentes de 400 nm de diamètre : (i) des anticorps monoclonaux dirigés contre un domaine constant de la chaine légère kappa du récepteur des LB, et (ii) des Ag modèles.Les SPAg se comportent comme des Ag particulaires naturels lorsqu'ils sont incubés in vitro avec des LB murins ou humains. Les SPAg se lient à la surface des LB kappa+, déclenchent un signal d'activation et sont internalisés dans leur endosomes. Les LB chargés en SPAg induisent l'activation et la prolifération des lymphocytes T CD4+ spécifiques de l'Ag in vitro.Des propriétés régulatrices peuvent être conférées aux LB chargés en SPAg en les stimulant avec du CpG. Les LB régulateurs générés n'induisent pas de prolifération des T CD4+ effecteurs mais, au contraire, entrainent une prolifération importante des Treg.Cette approche apparait comme une alternative innovante pour expandre des Treg spécifiques de l'Ag ex vivo / Allograft tolerance has been obtained in experimental models with adoptive transfer of ex vivo-expanded regulatory T cells (Treg) specific for donor antigens. Preclinical data have shown that Treg specific for indirectly presented alloantigens (indirect Treg) are mandatory for long-term tolerance. However, the ex vivo expansion of indirect Treg faces limitations,related essentially to the source of autologous antigen-presenting cells (APCs) used to stimulate T cells in vitro. B cells are (i) potent regulatory cells and (ii) APCs able to establish a privileged crosstalk with CD4+ T cells. However, the use of B cells as APCs is made problematic due to their inability to internalize and present non-cognate antigens. We have developed a novel nanobiotechnology-based approach to turn autologous polyclonal B cells into potent stimulators of antigen-specific T reg.Synthetic particulate antigens (SPAg) were generated by immobilizing (i) monoclonal antibodies directed against a framework region of B cell receptor (BCR) kappa-light chains and (ii) model antigens on fluorescent nanospheres of 400 nm in diameter.SPAg behaved like genuine particulate antigens when incubated in vitro with polyclonal murine B cells. SPAg bound to surface BCR of any kappa-positive B cells, triggered activation signal and were internalized in late endosomal compartment of B cells. SPAgloaded B cells induced activation and proliferation of antigen-specific T cells. This approach was transposable to humans’ cells. Importantly, regulatory properties could be conferred toSPAg-loaded B cells by CpG stimulation. SPAg-loaded regulatory B cells prevented proliferation of effector CD4+ T cells and induced proliferation of antigen-specific Treg in vitro.Autologous polyclonal B cells loaded with SPAg appear as an innovative platform to expand Treg ex vivo. This approach may improve the efficiency and costs of current procedures